SCHEMBL12879283

SCHEMBL12879283

NC[C@@H]1CC[C@@H](Oc2ccc3c(=O)[nH]ccc3c2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 13/20 1.00
PRKACA P17612 4/20 0.62
ROCK2 O75116 3/20 0.62
PRKCD Q05655 2/20 0.62
PRKG1 Q13976 1/20 0.62
PKN1 Q16512 1/20 0.62
PKN2 Q16513 1/20 0.62
AAK1 Q2M2I8 1/20 0.62
CDC42BPA Q5VT25 1/20 0.62
Q6ZSR9 Q6ZSR9 1/20 0.62
BMP2K Q9NSY1 1/20 0.62
CDC42BPB Q9Y5S2 1/20 0.62
PRKX P51817 1/20 0.58
PRKCE Q02156 1/20 0.58
PRKD1 Q15139 1/20 0.58
MAP2K1 Q02750 3/20 0.49
PRKACG P22612 3/20 0.36
PRKACB P22694 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12879276 1.00 ROCK1 (1.00) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1206229 1.00 ROCK1 (1.00) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL12879285 1.00 ROCK1 (1.00) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1206227 1.00 ROCK1 (1.00) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1204565 0.93 ROCK1 (0.86) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL12879240 0.86 ROCK1 (0.76) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1205635 0.85 ROCK1 (0.74) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1205028 0.85 ROCK1 (0.74) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1205709 0.85 ROCK1 (0.74) ROCK1PRKACAROCK2PRKCDPRKG1
SCHEMBL1206341 0.85 ROCK1 (0.74) ROCK1PRKACAROCK2PRKCDPRKG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893088-B2 6-substituted isoquinoline derivatives N.V. ORGANON (NL) 2011-02-22 US disclosed
US-7893088-B2 6-substituted isoquinoline derivatives N.V. ORGANON (NL) 2011-02-22 US disclosed
EP-2054389-B1 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS ORGANON NV (NL) 2010-04-07 EP disclosed
WO-2008020081-A1 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES AS ROCK-1 INHIBITORS N.V. ORGANON (NL) 2008-02-21 WO disclosed
US-20080045566-A1 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES N.V. ORGANON (NL) 2008-02-21 US disclosed
US-20080045566-A1 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES N.V. ORGANON (NL) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045566-A1 6-SUBSTITUTED ISOQUINOLINE DERIVATIVES ROCK1, ROCK2, RHOA ROCK1 1/4885PRKACA 2658/4885ROCK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.